A detailed history of Black Rock Inc. transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Black Rock Inc. holds 3,554,742 shares of ADCT stock, worth $7.07 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,554,742
Holding current value
$7.07 Million
% of portfolio
0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$2.55 - $5.09 $9.06 Million - $18.1 Million
3,554,742 New
3,554,742 $11.2 Million
Q3 2023

Nov 13, 2023

BUY
$0.72 - $2.37 $44,197 - $145,482
61,385 Added 13.1%
529,890 $476,000
Q2 2023

Aug 11, 2023

SELL
$1.9 - $2.66 $317,379 - $444,331
-167,042 Reduced 26.28%
468,505 $1.01 Million
Q1 2023

May 12, 2023

BUY
$1.92 - $5.45 $208,811 - $592,720
108,756 Added 20.64%
635,547 $1.24 Million
Q4 2022

Feb 13, 2023

BUY
$2.87 - $5.24 $283,914 - $518,367
98,925 Added 23.12%
526,791 $2.02 Million
Q3 2022

Nov 14, 2022

SELL
$4.66 - $10.31 $181,451 - $401,450
-38,938 Reduced 8.34%
427,866 $2.06 Million
Q2 2022

Aug 12, 2022

BUY
$5.96 - $14.99 $968,947 - $2.44 Million
162,575 Added 53.44%
466,804 $3.71 Million
Q1 2022

May 12, 2022

BUY
$13.28 - $20.03 $137,740 - $207,751
10,372 Added 3.53%
304,229 $4.47 Million
Q4 2021

Feb 10, 2022

SELL
$19.29 - $31.51 $381,633 - $623,393
-19,784 Reduced 6.31%
293,857 $5.94 Million
Q3 2021

Nov 09, 2021

BUY
$20.45 - $30.0 $263,866 - $387,090
12,903 Added 4.29%
313,641 $8.52 Million
Q2 2021

Aug 11, 2021

BUY
$20.38 - $27.04 $6.13 Million - $8.13 Million
300,738 New
300,738 $7.32 Million

Others Institutions Holding ADCT

About ADC Therapeutics SA


  • Ticker ADCT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,645,296
  • Market Cap $155M
  • Description
  • ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...
More about ADCT
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.